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Abstract
Purpose: To evaluate quality of life (QOL) and outcome of patients with anal carcinoma treated with short split-course 
chemoradiation (CRT).
Methods: From 1991 to 2005, 58 patients with anal cancer were curatively treated with CRT. External beam 
radiotherapy (52 Gy/26 fractions) with elective groin irradiation (24 Gy) was applied in 2 series divided by a median gap 
of 12 days. Chemotherapy including fluorouracil and Mitomycin-C was delivered in two sequences. Long-term QOL 
was assessed using the site-specific EORTC QLQ-CR29 and the global QLQ-C30 questionnaires.
Results: Five-year local control, colostomy-free survival, and overall survival were 78%, 94% and 80%, respectively. The 
global QOL score according to the QLQ-C30 was good with 70 out of 100. The QLQ-CR29 questionnaire revealed that 
77% of patients were mostly satisfied with their body image. Significant anal pain or fecal incontinence was 
infrequently reported. Skin toxicity grade 3 or 4 was present in 76% of patients and erectile dysfunction was reported in 
100% of male patients.
Conclusions: Short split-course CRT for anal carcinoma seems to be associated with good local control, survival and 
long-term global QOL. However, it is also associated with severe acute skin toxicity and sexual dysfunction. 
Implementation of modern techniques such as intensity-modulated radiation therapy (IMRT) might be considered to 
reduce toxicity.
Introduction
Sphincter-sparing chemoradiation (CRT) has evolved as
the standard of care for most patients with squamous cell
carcinoma of the anal canal. Combined CRT was first
introduced by Nigro et al. in the mid-1970s, and has
resulted in improved local and regional control, colos-
tomy free survival, and disease-free survival since then
[1-4]. Currently, local tumor control and disease-free sur-
vival have approximated 72% and 73%, respectively, in
randomized trials [4]. Mortality to incidence ratio was
14% (660 estimated deaths in the United States in 2006)
implying that the majority of patients with anal cancer
have a good prognosis [5]. Given these results, coupled
with the preservation of the rectum itself, maintaining
satisfactory ano-rectal function and controlling toxicity
have become important parameters in the evaluation of
CRT.
Sphincter-conserving CRT is associated with consider-
able acute and chronic complications. Split-course radio-
therapy with a planned gap was initially implemented to
select poor responders for surgery and good responders
f o r  b o o s t i n g  e i t h e r  w i t h  e x t e r n a l  b e a m  r a d i o t h e r a p y
(EBRT) or preferably brachytherapy. Split duration was 6
weeks, but was reduced in the recent years. Since there
were toxicity concerns the feasibility of reducing the gap
between sequences to 2 weeks was tested by the EORTC
phase II study 22953 [6]. Though acute toxicities have
been reported to be moderate and long-term toxicities to
be acceptable after 3 years, long-term QOL has not yet
been evaluated after this regimen.
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This study was conducted to evaluate QOL using the
newly implemented site-specific questionnaire QLQ-
CR29 of patients with anal canal cancer treated with
short split-course radiotherapy and concurrent chemo-
therapy with fluorouracil (5-FU) and Mitomycin C
(MMC). Secondary endpoints were acute toxicity, local
and regional tumor control, colostomy-free survival and
overall survival.
Methods
Patient characteristics
From 1991 to 2005, 58 consecutive patients with non-
metastatic cancer of the anal canal were treated curatively
with a short split-course of CRT at the Centre Hospitalier
de l'Université de Montréal (CHUM), Notre-Dame Hos-
pital. The histopathological diagnosis was established
according to the World Health Organization (WHO) cri-
teria [7]. Adenocarcinoma of the anal canal was excluded
because of its different behavior, management and prog-
nosis [8,9]. All patients had a complete work-up including
chest x-ray, CT-scan of the abdomen and pelvis, blood
analyses and rectoscopy with a tissue biopsy.
Treatment
All patients received curative CRT. Standard 3-dimen-
sional conformal whole pelvis external beam radiother-
apy (EBRT), using photons of 6 MV to 18 MV, was
delivered in two series. The first series of 24 Gy in 12
fractions was delivered via anterior and posterior parallel
opposed fields and encompassed macroscopic and micro-
scopic disease. Larger rectangular AP/PA fields with dis-
tal margin set to include the anal canal were used to
include the primary anal tumour, involved nodes and
nodal areas at risk including perirectal, external and
internal iliac and inguinal lymph nodes. After a planned
break of a median of 12 days, the second series of EBRT
(28 Gy/14 fractions) was applied to the macroscopic dis-
ease up to a total dose of 52 Gy. Chemotherapy consisted
of 5-FU delivered at a dose of 1000 mg/m2/day over 120
hours of continuous intravenous infusion on days 1 to 5
and days 29 to 33. At the same time, MMC was given at
10 mg/m2/day on day 1 and 29. Both were delivered in
the first week of each radiation therapy series.
Acute toxicity was retrospectively evaluated according
to the RTOG acute toxicity scale using the patient's chart.
QOL assessment
The long-term QOL was assessed by two standardized
EORTC questionnaires. The first one, QLQ-C30 version
3.0, is a validated questionnaire assessing cancer-specific
QOL [10]. The second one, QLQ-CR29, assesses site spe-
cific (ano-rectal) QOL [11]. The EORTC QLQ-CR29
questionnaire is based on EORTC QLQ-CR38 question-
naire and has been recently updated and modified based
on evidence from the literature, expert opinion and inter-
views with patients [11]. This study used the first version
of the QLQ-CR29 questionnaire. This module is a self-
rating questionnaire that comprises 29 questions. Two
questions are specific for patients with stoma and 2 more
questions are directed only to females or males. The prin-
cipal items of this questionnaire include urinary symp-
toms, pain, fecal incontinence, gastro-intestinal function,
stoma, male and female sex and body image. For all the
questions, a scale from 1 to 4 was used (1: not at all, 2: a
little, 3: quite a bit, 4: very much).
Statistics
All survival analyses were calculated according to the
Kaplan-Meier method. Overall survival was calculated
from time to diagnosis to death from any cause. Disease-
free survival was measured from date of diagnosis to
recurrence or death from all causes, or censored at last to
follow-up. Multivariate analysis was performed using the
Cox regression model. The variables tested were gender,
HIV status, T3-T4 vs T1-T2, N0 vs N-positive, 0-1 cycle
of 5-FU vs ≥ 2 cycles of 5-FU and 0-1 cycle of MMC vs ≥ 2
cycles of MMC. The SAS program was used for scoring
the QLQ-C30 according to EORTC QLQ-C30 scoring
manual [12]. All scores of the QLQ-C30 were linearly
transformed such that all scales range from 0 to 100. For
the six functional items, the higher score represents a
higher level of functioning and for the symptoms/single
items; a higher score means a higher level of symptoma-
tology/problems. For the QLQ-CR29, each question was
analyzed independently using the scale from 0 to 4 men-
tioned above.
Results
Among the 58 patients reported, 32 patients were female
and 26 patients were male with a median age of 53 years
(range 36-84). Fifty-seven patients had squamous-cell
carcinoma and 1 patient had undifferentiated carcinoma.
Patient characteristics are summarized in Table 1. Six
patients (10%) were HIV-positive and were receiving
highly active antiretroviral treatment. The T-Stage distri-
bution, according to the 2001 American Joint Committee
on Cancer/TNM classification, was T1 (9; 16%), T2 (22;
38%), T3 (13; 22%), T4 (13; 22%) and Tx (1; 2%) [13]. The
distribution according to the N-Stage was N0 (42; 72%),
N1 (5; 9%), N2 (5; 9%) and N3 (6; 10%). Sixteen percent (9
of 58 patients) had inguinal nodal involvement.
All but one (because of morbid obesity) patient with
negative inguinal lymph nodes received prophylactic
EBRT to the bilateral groins at a median dose of 24 Gy
(range 20-30 Gy). The median duration of the planned
break was 12 days (11-13 days (25-75 quartiles)). For the
second sequence of radiation therapy, most of the
patients were treated with a 3-field technique (41%), 4-Provencher et al. Radiation Oncology 2010, 5:41
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field technique (40%) or an AP/PA technique (19%). The
total radiation dose delivered to the macroscopic disease
was 52 Gy (range 42-78 Gy). The median duration of the
CRT was 48 days (range 42-78). Two patients with a T4
tumor received a boost of external beam radiation of 9 Gy
and 10 Gy directed to the primary tumor with another
concurrent cycle of 5-FU and MMC for persistent dis-
ease. Ninety-five and 89% completed the two required
cycles of 5-FU and MMC respectively.
Tumor control and survival
Median follow-up time was 3 years (range 0.5-10 years).
At 5 years, overall survival, disease-free survival (DFS)
and colostomy-free survival rates for all 58 evaluable
patients were 80%, 74%, and 94% respectively. Local con-
trol at five years according to T-Stage was T1-88%, T2-
100%, T3-54% and T4-50%. The local and the regional
control according to the node-status was N0-75% and
88% and N(1-3)-85% and 93% respectively. Among the
eleven patients who had a local relapse, 7 had isolated
local relapse and 4 had a synchronous local and regional
relapse. Four out of 11 patients underwent salvage
abdomino-perineal surgery without further relapse. Of
the other 7 patients, 2 refused surgery and received palli-
ative care, one was not a candidate for surgery, 3 were lost
at follow-up and one has not yet been operated upon for
his local relapse. Only two patients (3%) developed dis-
tant disease; a T1N0 patient developed liver metastasis
and a T3N2 patient presented with bone metastasis.
Prognostic factors
The variables tested at multivariate analysis were gender,
HIV status, T3-T4 vs. T1-T2, N0 vs. N-positive, 0-1 cycle
of 5-FU vs. ≥ 2 cycles of 5-FU and 0-1 cycle of MMC vs. ≥
2 cycles of MMC. This analysis showed that stage T3-T4
was the only factor statistically associated with a worse
local control and disease-free survival. This may be
explained in part by the low number of patients per sub-
groups.
Acute toxicity
Grade 3 and 4 skin toxicity, according to the RTOG scale,
was reported in 81% and 2% of patients respectively.
Ninety percent of women and 76% of men presented with
grade 3 or 4 skin toxicity. Most of the acute gastrointesti-
nal toxicity was grade 2 with only 2% and 4% reporting
grade 3 and 4 toxicity respectively. There was no grade 3
or 4 genito-urinary toxicity. Eighty-six percent of patients
reported no hematological toxicity while 7% had grade 3
or 4 toxicity.
Quality of life (QOL)
At the time when the QOL questionnaires were sent out,
12 patients were deceased and 2 were alive with local
recurrence. Fourteen patients were lost to follow-up
(32%; 14/44 patients) due to the broad assessment time in
which many patients had moved or were followed at
another institution. Responses of both questionnaires
were received from 30 patients and among them, there
Table 1: Patient caracteristics
Number of patients
(%)
N-Stage
N0 N1 N2 N3
Gender
F 32 (55)
M 26 (45)
Median age (years) 53 (36-84)
HIV+ 6 (10)
Histology
Squamous cell 57 (98)
undifferentiated 1 (2)
T-Stage
T1 9 (16) 9 0 0 0
T2 22 (38) 17 1 2 2
T 3 1 3  ( 2 2 ) 7222
T 4 1 3  ( 2 2 ) 9211
T x 1  ( 2 ) 0001
Patient characteristics (n = 58). F = female, M = male.Provencher et al. Radiation Oncology 2010, 5:41
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were no missing values. The median time between the
last treatment of radiation therapy and the completion of
the questionnaires was 51 (range 15-132) months.
Ninety-five percent of patients answered the question-
naires at least 2 years after the end of the treatment.
The general EORTC QLQ-C30 functional and symp-
tom scales and responses are shown in Table 2. Global
functional QOL score was 70, with 100 being the best
score. Functional aspects such as general physical and
cognitive functions were excellent with scores above 80.
Emotional, social and role functions seemed to be good
after treatment with short split-course CRT. Gastro-
intestinal symptoms including nausea/vomiting, consti-
pation and/or appetite loss were reported to be very low,
while diarrhea was frequently reported. Other symptoms
commonly reported by the general population like
fatigue, dyspnoea, pain, and financial problems were
commonly reported. There were no changes over time in
regard to the global functional QOL score, evaluated
before or after 5 years from completion of the treatment.
The results from the disease-specific QLQ-CR29 (Table
3) revealed that 77% were satisfied with their body. This
includes 60% to a great extent while 17% were a little dis-
satisfied. Twenty-three percent of patients were very
much dissatisfied. The most common symptom was
increased urinary frequency (40%), although only in 10%
of patients to a maximum extent. Significant anal pain or
fecal incontinence was rarely reported though 47% suf-
fered some form of fecal incontinence. Only 17% com-
plained of a disturbing involuntary loss of stool. Three
patients with a stoma answered the questionnaire and
they reported no problem in caring for their stoma. Fifty
percent of patients maintained an interest in having sex-
ual relations but 100% of male patients had difficulty
maintaining an erection. Forty-four percent of men quali-
fied the erectile dysfunction as severe (# 4 on the scale:
very much). Among women, 65% had no interest at all in
sexual relations, 21% a little, and only 14% had a moderate
interest. For those women who maintained an interest in
having sexual relations, 50% reported having pain or dis-
comfort during intercourse. The majority of the patients
did not suffer from non-satisfaction regarding their body
or loss of masculinity or femininity in relation to their
cancer or the treatment.
Discussion
Shortening the break inherent in split-course chemoradi-
ation for anal cancer from 6 to 2 weeks has resulted in
acceptable acute and chronic toxicities, though long-term
QOL has yet to be evaluated for this regimen [14,15]. The
EORTC phase II study 22953 demonstrated a severe long-
term toxicity rate of 16% at 3 years from short split-
course CRT. This included 4 patients suffering from
ulceration and 1 patient from stenosis. Taking these
results into consideration, we undertook a study designed
to allow formal assessment of QOL in an unselected
homogenous group of patients treated at our institution
with split-course CRT. We report that such a short split-
course CRT regimen is feasible with acceptable site spe-
cific (ano-rectal) long-term quality of life assessed with
the QLQ-CR29 questionnaire. Increased urinary fre-
quency and sexual dysfunction were the most frequent
complaints. Five-year overall survival and colostomy-free
survival for the whole group were very good approaching
80% and 94%, respectively. This is the first study using the
QLQ-CR29 in addition to the QLQ-C30 questionnaire to
e v a l u a t e  Q O L  o f  p a t i e n t s  w i t h  a n a l  c a n a l  c a r c i n o m a
treated with standard short split-course CRT.
There are some limitations to the current study. This
study is a cross-sectional investigation of QoL with inher-
ent limitations such as missing base-line QoL data and a
bias due to different follow-up times. Results of QoL
might differ when assessed after either a short or a long
follow-up. The prevalence of missing data (32%) for the
QLQ-C30 and the QLQ-CR29 questionnaires in this
study appears to be high but is similar to other studies.
The study of Allal et al. did not obtain the answers to the
questionnaires of 11 out of 52 (21%) patients [14]. Jeph-
cott et al. had a missing data rate of 45% (42/92 patients)
[15]. The percentage of patients with T4 tumors in our
series (22%) seems higher than in others (10-15%).
Three other studies evaluated QOL of anal cancer
patients using the former EORTC QLQ-CR38 question-
naire after different treatment regimens (Allal et al., Jeph-
cott et al., Oehler-Jänne et al.) [14-16]. These series used
either 5.5 week split-course RT (11 patients) or CRT (30
patients) (Allal et al); 3.5 week split-course CRT (50
patients) compared to 50 healthy volunteers (Jephcott et
al.); or 3 week split-course CRT (34 patients) compared
with continuous CRT (47 patients) (Oehler-Jänne et al).
In terms of general functioning and symptoms as evalu-
ated by the QLQ-C30 questionnaire, our results are com-
parable with the results of the other 3 studies. Most
important, overall QOL score and functional or symptom
scores were good and not different from the scores of the
healthy volunteer group reported by Jephcott et al. The
site specific (ano-rectal) questionnaire QLQ-CR29
revealed that the majority of patients (77%) remained sat-
isfied regarding their body in relation to their cancer or
the treatment. Despite shortening the split, side-effects
were infrequent with respect to significant involuntary
loss of stool (17%) or anal pain (17%). These results are
comparable with the observation by Allal et al, Jephcott et
al and Oehler-Janne et al. where defecation problems
were reported 18%, 20% and 21.4% respectively. Our sub-
jective results are similar to the data from Vordermark et
al. who evaluated continence by performing anorectal
manometry in 16 patients with anal canal cancer treatedProvencher et al. Radiation Oncology 2010, 5:41
http://www.ro-journal.com/content/5/1/41
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with split course CRT [17]. Fifty-six percent were com-
pletely continent, 19% had liquid or solid soiling, and 6%
were incontinent.
Our study showed that sexual dysfunction was very
common. All men reported erectile dysfunction (100%)
a n d  o n l y  5 0 %  m a i n t a i n e d  a n  i n t e r e s t  i n  h a v i n g  s e x u a l
relations. For those women (35%) who maintained an
interest in having sexual relations, 50% reported having
pain or discomfort during intercourse. Accordingly, Allal
et al. and Jephcott et al. as well showed a low score for
sexual functioning, 13 and 24 (100 being the best score)
respectively. Both groups used the EORTC QLQ-CR38
questionnaire. Only 35% (14/41 patients) in the study of
Allal et al. reported some sexual activity. In our series, the
median age of the male population was 52 which does not
explain the high rate of erectile dysfunction. Erectile dys-
function (ED) is also found to be a common sequela after
external beam radiotherapy and brachytherapy for pros-
tate cancer [18]. It is controversial whether RT dose to
sensitive structures like neurovascular bundles (NVBs),
internal pudendal arteries (IPAs), accessory pudendal
arteries, corpora cavernosa and the penile bulb is respon-
Table 2: EORTC QLQ-C30
CHUM
N = 30 
[Standard 
Deviation]
GUH [14]
N = 41
BCCA 
[15]Patients
N = 50
BCCA 
Volunteers
N = 50
Zurich 
[16]EBRT
N = 47
Zurich BT
N = 34
Functional 
scales
Global quality 
of life
70 [± 25] 71 [± 21] 66 [± 28] 78 [± 20] 86 [± 22] 72 [± 23]
Physical 
function
87 [± 14] 79.5 [± 22] 74 [± 29] 89 [± 14] 78 [± 27] 76 [± 31]
Role function 77 [± 26] 85 [± 21] 76 [± 33] 87 [± 25] 77 [± 32] 66 [± 37]
Emotional 
function
77 [± 26] 77 [± 25] 74 [± 28] 81 [± 16] 80 [± 24] 77 [± 25]
Cognitive 
function
85 [± 25] 76 [± 23] 75 [± 24] 82 [± 20] 75 [± 34] 78 [± 36]
Social 
function
74 [± 34] 82 [± 28] 73 [± 35] 90 [± 20] 77 [± 32] 70 [± 36]
Symptoms 
scales
Fatigue 28 [± 29] 27 [± 22] 36 [± 30] 20 [± 21] 27 [± 9] 29 [± 11]
Pain 20 [± 25] 15 [± 21] 6 [± 17] 1 [± 14] 7 [± 2] 24 [± 15]
Nausea, 
vomiting
1 [± 4] 6 [± 15] 23 [± 15] 14 [± 22] 1 [± 0] 2 [± 0]
Single items
Dyspnea 18 [± 26] 13 [± 22] 23 [± 33] 8 [± 16] 16 [± 7] 18 [± 7]
Sleep 
disturbance
26 [± 31] 23.5 [± 29] 29 [± 32] 22 [± 28] 29 [± 15] 33 [± 16]
Appetite loss 10 [± 23] 10 [± 19] 13 [± 22] 3 [± 15] 8 [± 3] 8 [± 3]
Diarrhea 28 [± 40] 28 [± 36] 27 [± 32] 5 [± 12] 24 [± 9] 29 [± 9]
Constipation 7 [± 19] 15 [± 21] 24 [± 32] 8 [± 16]
Financial 
impact
20 [± 31] 15 [± 28] 23 [± 37] 8 [± 20 13 [± 6] 17 [± 10]
EORTC QLQ-C30 results of this study and of the literature. The questionnaire assesses cancer-specific QOL. For all the questions, a scale from 
1 to 4 was used (1: not at all, 2: a little, 3: quite a bit, 4: very much). All scores were linearly transformed such that all scales range from 0 to 100. 
For the six functional items, the higher score represents a higher level of functioning and for the symptoms/single items, a higher score means 
a higher level of symptomatology/problems. Brackets indicate "standard deviation". N = number of patients.Provencher et al. Radiation Oncology 2010, 5:41
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sible for the high frequency of sexual dysfunction in the
male population. So far , no correlation has been found
between sexual dysfunction and RT dose to NVBs or
IPAs and contradicting results regarding RT dose to cor-
pora cavernosa and penile bulb. Our study as well as the
studies mentioned above used an AP/PA technique
whereby dose to the penile bulb may be assumed to be
high. Sparing of the penile bulb could be achieved using
intensity-modulated radiation therapy (IMRT) which is
an investigational technique for the treatment of anal
canal carcinoma and there is no long term QOL data
available yet. On the other hand, sparing of the penile
bulb to improve potency-preservation is not sufficiently
supported by the current literature. In prostate cancer,
use of IMRT compared favorably to previously reported
series using conventional external beam radiation therapy
techniques in preserving erectile function, although no
correlation with RT dose was found [19]. In conclusion,
shortening the radiation gap from 4-6 weeks to 12 days
does not seem to result in worse QOL.
We were able to reproduce the good outcome of the
EORTC phase II trial. Five-year overall survival and
colostomy-free survival for the whole group in our series
were 80% and 94%, as compared to 81% and 81% (at 3
years), respectively, in the EORTC study [6]. Results from
randomized trials which used a 6 weeks split-course CRT
regimen showed an overall survival ranging from 57% to
75% and a colostomy-free survival ranging from 71% to
72% [2-4].
Regarding side effects, severe gastrointestinal toxicity
(4% vs. 12%) and hematological toxicity (7% vs. 2%) were
c o m p a r a b l e  w i t h  t h e  E O R T C  s t u d y .  H o w e v e r ,  r a t e  o f
acute skin toxicity was relatively high in our study with
81% (grade 3) and 2% (grade 4) as compared to 28%
reported by Bosset et al. Total RT dose was not higher in
our study (52 Gy vs. 59.4 Gy). Differences in the RT tech-
niques might explain the increase in the severe dermatitis
rate. We used elective RT to the groins whereas Bosset et
al. irradiated the inguinal region only when the primary
tumor was located less than 1 cm from the anal margin,
or when the inguinal and/or the pelvic nodes were clini-
c a l l y  p o s i t i v e  [ 6 ] .  A  r e d u c t i o n  i n  t o x i c i t i e s  m i g h t  b e
achieved using IMRT which has been shown in a recent
study by Salama et al. where they reported grade 3 skin
desquamation and grade 3 acute gastrointestinal toxici-
ties in 38% and 15%, respectively [20].
Elective groin irradiation is controversial. While in
North America, prophylactic inguinal irradiation is a rou-
tine practice and the RTOG protocols recommend 30.6
Gy in 17 fractions to this area, in Europe, it is not widely
applied and the EORTC study by Bosset et al. did not
apply it. The regional failure rate, either isolated or asso-
ciated with a local or a distant relapse, was 12%. It has to
be pointed out that in our study, prophylactic dose to
microscopic disease including groins was rather small
with a median dose of 24 Gy (range 20-30 Gy). Inguinal
relapse was observed in 3 of 58 patients (5%) without
groin involvement at the time of initial presentation (1
patient T1N0 and 2 patients T4N0). Similar inguinal fail-
ure rates have been reported after CRT including elective
groin irradiation in a series of 276 patients at the Institut
Curie de Paris and at other institutions [21-24].
The prospective non-randomized study from Cum-
mings et al. reported the results of different radiation
Table 3: QLQ-CR29
1
Not at all
2
A little
3
Quite a bit
4
very much
Difficulty having or 
maintaining an 
erection
0% 44% 12% 44%
Fecal incontinence 53% 30% 7% 10%
Anal/perinal pain 60% 23% 10% 7%
Urinary frequency 33% 27% 30% 10%
Blood in stools 83% 17% 0% 0%
Feeling less feminine/
masculine as a result of 
the disease or 
treatment
70% 7% 3% 20%
Dissatisfied with your 
body
60% 17% 0% 23%
EORTC QlQ-CR29 results of this study (n = 30 patients): The questionnaire assesses site specific (ano-rectal) QOL. For each questions, a scale 
from 1 to 4 was used (1: not at all, 2: a little, 3: quite a bit, 4: very much). n = number of patients.Provencher et al. Radiation Oncology 2010, 5:41
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therapy and chemotherapy protocols [25]. Fifty-three out
of 192 patients received split course CRT with 5-FU and
MMC (2 × 25 Gy: 14 patients, 2 × 24 Gy: 33 and 3 × 20
Gy: 6). In this subgroup, the regional recurrence was 9%.
The EORTC trial gave 45 Gy to microscopic disease com-
bined with 5-FU and MMC followed by a boost of 15 Gy
or 20 Gy to macroscopic disease for complete and partial
responders respectively, after a break of six weeks [2].
The loco-regional relapses were 32% and the majority had
an isolated local recurrence. Prophylactic radiation ther-
apy of 24 Gy combined with 5-FU and MMC seems ade-
quate to control microscopic disease. However, after CRT
without elective RT to the groins, metachronous inguinal
metastases have been reported in only 19 out of 243
patients (7.8%) in a series of 270 from Gerard et al. [26].
The EORTC study 22953 reported no inguinal failure.
The low rate of inguinal relapses found in this series
could also be explained by low propensity of this disease
to cause inguinal metastases even without prophylactic
irradiation.
Conclusion
In conclusion, short split-course CRT for anal canal carci-
noma seems to be associated with good long-term global
QOL, though increased micturition and sexual dysfunc-
tion remained important problems. Local control, colos-
tomy-free and overall survival were excellent but acute
skin toxicity noticeably high. Implementation of modern
RT techniques such as IMRT and reduction of RT dose to
the groins might have the potential to improve acute tox-
icity and late morbidity.
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